Contract Service Providers Gear Up to Develop Emerging Therapies

Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Jun 15, 2016
By BioPharm International Editors
Volume 2016 ebook, Issue 1, pg 10–17

Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies. 

The panelists in this roundtable discussion included: John Allinson, head of biomarker strategy, drug development services at LGC; Martha S. Rook, head of novel therapies, process solutions, MilliporeSigma; Joe Codamo, general manager, Patheon; Brian Hampson, Vice-President, Global Manufacturing Sciences and Technology, PCT, a Caladrius Company; Stephen Gacheru, Executive Director–Biopharmaceutical Product Development, PPD Laboratories; Bruce Stauffer, Executive Director–Immunochemistry Department, PPD Laboratories; and Mark Rogers, VP USA–Life Science, SGS.

Read this article and other articles in BioPharm International's 2016 Outsourcing Resources eBook.

 

 

 

native1_300x100
lorem ipsum